Dr. Betts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
500 Harvard St SE
Minneapolis, MN 55455Phone+1 612-273-3000- Is this information wrong?
Summary
- Dr. Brian Betts is a hematologist in Minneapolis, MN and is affiliated with University of Minnesota. He received his medical degree from Eastern Virginia Medical School and has been in practice 16 years. He specializes in hematologic oncology and is experienced in graft-versus-host disease, stem cell transplantation, leukemia, and cell therapy.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of MinnesotaResidency, Internal Medicine, 2004 - 2007
Eastern Virginia Medical SchoolClass of 2004
Certifications & Licensure
NY State Medical License 2008 - 2025
MN State Medical License 2018 - 2024
FL State Medical License 2011 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.Boucher, J., Shrestha, B., Vishwasrao, P., Cervantes, E., Ghafoor, T., Reid, K., Spitler, K., Yu, B., Guevara-Patino, J., Leick, M., Betts, B., Maus, M., Davila, M.> ;Molecular Therapy Oncolytics. 2023 Dec 19
- 3 citationsPhase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph E Maakaron, Brian C Betts, Armin Rashidi, Mark B Juckett, Troy Lund, Veroni...> ;Transplantation and Cellular Therapy. 2023 Sep 1
- 2 citationsPhase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction ...Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph Maakaron, Brian C Betts, Armin Rashidi, Mark Juckett, Troy Lund, Veronika B...> ;Medrxiv. 2023 Mar 29
- Join now to see all
Press Mentions
VITRAC Therapeutics Initiates a Phase 1/2 Clinical Trial with the Aurora Kinase a Inhibitor VIC-1911 in GVHD ProphylaxisApril 26th, 2022- Experts in Transplantation, Engineered Cells and Pediatrics Join Growing Roswell Park Cell Therapy ProgramDecember 7th, 2023
- Inside Roswell Park's Big Bet on Cell Therapy and What That Means for Cancer CareApril 4th, 2024
Hospital Affiliations
M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
Roswell Park Comprehensive Cancer CenterBuffalo, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
